Alpha-bloquants

Leflunomide is a drug that belongs to the class of pyridones. It is used in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis. Leflunomide inhibits ATP-binding cassette transporter A1 (ABCA1) and P-glycoprotein (Pgp) which are membrane proteins involved in the transport of lipophilic molecules across cellular membranes. Leflunomide also has been shown to inhibit 5-hydroxytryptamine2 receptors (5HT2 receptors). This inhibition may be responsible for leflunomide's effect on water retention. Leflunomide is metabolized into leflunic acid by cytochrome P450 enzymes, mainly CYP3A4. The activity of leflunic acid is similar to that of leflunomide.

N2-Methyl alfuzosin-D7 is a drug product that belongs to the group of alfuzosin, which is a selective inhibitor of the enzyme phosphodiesterase type 5 (PDE5) and is used for the treatment of benign prostatic hyperplasia. It has been designed to reduce the risk of adverse effects associated with other PDE5 inhibitors, such as erectile dysfunction and urinary retention. N2-Methyl alfuzosin-D7 has been shown to be effective in animal studies and in vitro experiments. However, its metabolism remains unknown.

Mirtazapine N-oxide is an antidepressant agent that is metabolized to mirtazapine. Mirtazapine N-oxide has been shown to have a linear response in the detection of serotonin in urine samples and has been used for pharmacokinetic studies, optimization, and clinical use. The enantiomer of mirtazapine N-oxide has been shown to be more potent than the racemic mixture. The drug is excreted unchanged into the urine with a half-life of 2 hours. Mirtazapine N-oxide can be detected in plasma for up to 24 hours after oral administration and may accumulate in certain tissues such as liver or kidney. This drug has also been shown to cause death in mice at very high doses.

Silodosin (KAD 3213) is an alpha-Adrenergic Blocker. The mechanism of action of silodosin is as an Adrenergic alpha-Antagonist.